Prime Medicine Inc. Company Profile
NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Prime Medicine at a glance
Prime Medicine Inc. (NASDAQ: PRME) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Prime Medicine is led by Dr. Allan Reine M.D. and employs about 146 people. The company's shares have traded publicly since 2022.
At a market capitalization of $791.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001894562, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Prime Medicine do?
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Prime Medicine Inc.
- Ticker
- NASDAQ: PRME
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Allan Reine M.D.
- Employees
- 146
- Headquarters
- 60 First Street, Cambridge, MA, United States
- Phone
- 617 465 0013
- Website
- primemedicine.com
- IPO year
- 2022
- Market cap
- $791.62M
- SEC CIK
- 0001894562
- Latest annual report
- 10-K · Mar 3, 2026
Companies similar to Prime Medicine
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs PRME |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs PRME |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs PRME |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs PRME |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs PRME |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs PRME |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs PRME |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs PRME |